• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Body weight changes and psychotropic drug treatment: neuroleptics].

作者信息

Recasens C

机构信息

Service de Psychiatrie, Hôpital A. Chenevier, 40, rue de Mesly, 94000 Créteil.

出版信息

Encephale. 2001 May-Jun;27(3):269-76.

PMID:11488257
Abstract

Weight gain associated with neuroleptics or antipsychotic treatment is well known by psychiatrists, but is too rarely considered as justifying a specific treatment program. Overweight is a risk factor for somatic disorders and can have a negative influence on self-esteem and self-confidence. This can lead to poor observance, and relapse of psychotic symptoms. Some studies try to describe the weight fluctuations according to the different neuroleptics and taking into account other variables like treatment duration, age or sex. Mechanisms of weight gain are less studied, in spite of evidence that neuroleptics interact with receptors of dopamine, norepinephrine, serotonin, histamine and acetylcholin, all implicated in a way or another, in weight regulation. Antipsychotics, like clozapine and olanzapine, are more concerned with neuroendocrine and neurovegetative interactions, and are responsible for the most severe weight increases. Loxapine and molindone induce weight decreases, and these exceptions are difficult to explain. The paper discusses the clinical and the epidemiological data, and indicates the methodological problems for such studies. Some hypotheses about the pathophysiological aspects of this side effect are made, in regard to growing knowledge about the biological mechanisms of weight regulation. Some solutions for a better consideration and caretaking of patients with such problems or "at risk" treatment are proposed.

摘要

相似文献

1
[Body weight changes and psychotropic drug treatment: neuroleptics].
Encephale. 2001 May-Jun;27(3):269-76.
2
Antipsychotic-associated weight gain and clinical outcome parameters.抗精神病药物相关的体重增加及临床结局参数。
J Clin Psychiatry. 2001;62 Suppl 7:11-21.
3
Weight gain associated with use of psychotropic medications.与使用精神药物相关的体重增加。
J Clin Psychiatry. 1999;60 Suppl 21:16-9.
4
Using antipsychotic agents in older patients.在老年患者中使用抗精神病药物。
J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4.
5
[Atypical antipsychotic-induced weight gain].非典型抗精神病药物所致体重增加
Psychiatr Pol. 2006 Sep-Oct;40(5):995-1007.
6
Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.抗精神病药物治疗期间的肥胖及相关代谢异常:机制、管理与研究展望
Pharmacopsychiatry. 2002 Nov;35(6):205-19. doi: 10.1055/s-2002-36391.
7
The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.专家共识指南系列。优化精神障碍的药物治疗。引言:方法、评论与总结。
J Clin Psychiatry. 2003;64 Suppl 12:5-19.
8
[Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].[法国13家精神病医院抗精神病药物的处方模式]
Encephale. 2009 Apr;35(2):129-38. doi: 10.1016/j.encep.2008.03.007. Epub 2008 Jul 7.
9
Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle.非典型抗精神病药物所致体重增加的遗传学剖析:药物遗传学谜题的新初步数据
J Clin Psychiatry. 2001;62 Suppl 23:45-66.
10
Weight gain and antipsychotic medication.
J Clin Psychiatry. 2000;61 Suppl 8:36-41; discussion 42.

引用本文的文献

1
In vivo pharmacological evaluations of novel olanzapine analogues in rats: a potential new avenue for the treatment of schizophrenia.新型奥氮平类似物在大鼠体内的药理学评价:治疗精神分裂症的新途径。
PLoS One. 2013 Dec 11;8(12):e80979. doi: 10.1371/journal.pone.0080979. eCollection 2013.
2
Novel olanzapine analogues presenting a reduced H1 receptor affinity and retained 5HT2A/D2 binding affinity ratio.具有降低的H1受体亲和力并保留5HT2A/D2结合亲和力比值的新型奥氮平类似物。
BMC Pharmacol. 2012 Jun 22;12:8. doi: 10.1186/1471-2210-12-8.